News | MRI Breast | October 31, 2017

Study Finds Women With High Breast Cancer Risk Declining MRI Screening

Even with common access barriers removed in a military health system, most of the women with a higher lifetime risk of the disease are declining MRI scans

Study Finds Women With High Breast Cancer Risk Declining MRI Screening

October 31, 2017 — Some women, because of genetic predisposition, personal or family history, have a higher than average lifetime risk of developing breast cancer. For those women, earlier magnetic resonance imaging (MRI) is recommended for cancer screening.

But according to new findings presented at the American College of Surgeons Clinical Congress 2017, Oct. 22-26 in San Diego, the vast majority of women in one health system who are at higher risk of breast cancer choose not to get breast MRI screenings, even when the service was available to them at no cost.

"The military health system is an equal-access, no-cost system. This system allows us to study how well we are doing in terms of truly adhering to the current recommended guidelines for screening of breast cancer," said lead study author Vance Sohn, M.D., a surgical oncologist at Madigan Army Medical Center, Tacoma, Wash.

For the study, investigators from Madigan Army Medical Center analyzed data on 1,057 women who had a 20 percent or greater lifetime risk of developing breast cancer. The screenings were offered based on their high-risk status, and not because of mammography results. Between 2015 and 2016, these women were offered MRI screenings. The aim of this analysis was to assess whether these higher risk women actually got the imaging test. Overall, the study showed that only 23 percent (247 women) underwent MRI screening.

Further, when results were expressed in quartiles, researchers found that just 15 percent of women with a 20 to 24 percent lifetime risk of breast cancer had an MRI; 24 percent of those with a 25 to 29 percent risk got the imaging test; 36 percent of women with a 30 to 39 percent risk sought an MRI; and only half of the women with more than a 40 percent lifetime risk of developing breast cancer chose to get this recommended screening.

"In the interest of helping more women be screened earlier for breast cancer, we were intrigued about what this preliminary study identified — that 85 percent of women with a 20 to 24 percent lifetime risk still did not pursue high-risk surveillance," Sohn reported. "Ultimately, the question we are really trying to answer is why women at high risk for breast cancer are declining MRI screening. That issue is the next phase of this study."

Sohn and his team plan further research to find out why, on an individual basis, women are declining this cancer check. Is it confusion about the screening tool itself and its safety? Are they afraid of what the test might reveal?

"If we understand the reason behind this circumstance, it will help us better target those who would benefit from this imaging modality so we could provide clear explanations about the test," Sohn said. "The general sense is that patients are just too busy, but discovering the reason will be a very important piece to this puzzle."

Although this was a military health system study, Sohn said he does not think their findings are unique to the military. "In fact, I imagine our compliance rate is even higher than most. Within the civilian healthcare system, there are fiscal implications such as the cost of the MRI and future health insurance implications, that we are controlling for," he said.

In general, when it comes to breast cancer screening more is not necessarily better. In the past, the misuse of screening MRIs has created much anxiety in women, leading clinicians to perform further testing for tiny spots that turn out to be benign. To target patients for appropriate testing, clinicians and patients alike need a full understanding of the pros and cons of MRI screening. Clinicians then can develop personalized screening plans.

What the study does highlight is that the appropriate application of this imaging technology is very important, Sohn said.

"So maybe the 20 to 24 percent lifetime risk isn't really appropriate, maybe it should be even higher than what the organizations are recommending. In other words, what is the appropriate cutoff?

Ultimately, that is really what we are trying to decipher," he concluded.

For more information: www.facs.org

Related Content

Christopher Comstock, M.D., ECOG-ACRIN Cancer Research Group study published in JAMA builds evidence for use of abbreviated MRI in women with dense breasts

Christopher Comstock, M.D., (Memorial Sloan Kettering Cancer Center) is the lead author of a paper in JAMA that reports that abbreviated breast MRI detected significantly more (almost 2 and a half times as many) breast cancers than digital breast tomosynthesis (3-D mammography) in average-risk women with dense breasts. Photo courtesy of Memorial Sloan Kettering Cancer Center

News | Breast Imaging | February 26, 2020
February 26, 2020 — According to a study
Women 75-plus May Not Benefit from Breast Cancer Screening
News | Mammography | February 25, 2020
February 25, 2020 — According to newly published research in an article titled...
An example of the MRI scans showing long-term and short-term survival indications. #MRI

An example of the MRI scans showing long-term and short-term survival indications. Image courtesy of Case Western Reserve University

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — ...
A cutting-edge magnet resonance imaging (MRI) technique to detect iron deposits in different brain regions can track declines in thinking, memory and movement in people with Parkinson's disease #Parkinsons #MRI

Summary steps of the processing pipeline for QSM reconstruction (phase pre-processing and map estimation) and whole brain/regional analysis. ANTs, advanced normalisation tools; MP-RAGE, magnetisation-prepared, 3D, rapid, gradient-echo; MSDI, multi-scale dipole inversion; QSM, quantitative susceptibility mapping; ROI, region of interest; SWI, susceptibility weighted imaging.

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — A cutting-edge...
Recognized as the “Pulitzer Prize of the business press,” the Jesse H. Neal Award finalists are selected for exhibiting journalistic enterprise, service to the industry and editorial craftsmanship
News | Radiology Business | February 19, 2020
February 19, 2020 — Connectiv, a division of The Software and Information Industry Association (SIIA), has announced
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast

Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast. A small mass with micro-calcifications on the right-side breast was detected correctly by AI with an abnormality score of 96%. This case was recalled by 7 out of 14 radiologists (4 breast radiologists and 3 general radiologists) initially (without AI) and all 14 radiologists recalled this case correctly with the assistance of AI.

News | Artificial Intelligence | February 11, 2020
February 11, 2020 — A new study, published in...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
Sponsored Content | Videos | Artificial Intelligence | February 06, 2020
ProFound AI is an FDA-cleared artificial intelligence (AI) system for reading 3-D breast tomosynthesis images.